4-(2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)morpholine, 95.0%, 100mg

4-methyl-5-(1H-pyrrol-1-yl)nicotinic acid, 95.0%, 500mg

5-Bromo-2-cyclopropoxypyridine, 97%, 250mg

(4S,4'S)-2,2'-(1,3-BIS(4-(TERT-BUTYL)PHENYL)PROPANE-2,2-DIYL)BIS(4-BENZYL-4,5-DIHYDROOXAZOLE), 95%, 1g

4-(3-chlorophenyl)-1H-pyrazol-5-amine, 95.0%, 25g

(2E)-3-(2-ethoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one, 95.0%, 10g

13-cis-Retinoic Acid, >95%, 25g

3-Phenyl-1-propyne (stabilised with BHT), 95.0%, 1g

Vinylmethylsiloxane-dimethylsiloxane copolymer trimethysiloxy terminated cSt 800-1200, 100g

Ethyl 5-cyanonicotinate, 97%, 100mg

Benzene, 1-chloro-2-nitro-4-(phenylmethoxy)-, 98%, 100mg

5-Bromo-4-fluoro-m-xylene, 95.0%, 5g

3-Amino-2H-chromen-2-one, 97.0%, 1g